Every material Form 8-K GRAIL, Inc. has filed with the SEC since June 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GRAIL reported third-quarter 2026 results on November 4, 2026. Total revenue grew 4% to $37.5 million, but net loss widened 16% to $103.6 million and gross loss grew 32% to $18.1 million. The company said an FDA decision on Galleri is anticipated by early Q1 2027, following a favorable September Advisory Committee vote.
Galleri test revenue rose 14% year over year to $37.3 million, and Galleri test volume rose about 24% to more than 56,000 tests.
Net loss was $103.6 million, up $14.6 million, or 16%; loss per share was $(2.21), compared with $(2.46) a year earlier.
Adjusted gross profit fell 20% to $15.9 million, and adjusted EBITDA was $(92.6) million, an increase in loss of $20.9 million.
Cash, cash equivalents and short-term marketable securities totaled $788.7 million as of September 30, 2026.
GRAIL reported second-quarter 2026 results, with total revenue up 26% year over year to $44.7 million and Galleri test revenue up 24% to $42.6 million. Net loss narrowed slightly to $110.2 million, but adjusted EBITDA loss widened to $90.3 million, and the company said it anticipates an FDA advisory committee in the fall for its Galleri PMA application.
Total revenue rose 26% to $44.7 million; Galleri test volume grew 35% to more than 61,000 in the quarter.
Net loss was $110.2 million versus $114.0 million a year earlier; gross loss narrowed 29% to $12.6 million.
Adjusted EBITDA loss was $90.3 million, up $11.9 million (15%) from the prior-year quarter.
Cash, cash equivalents and short-term marketable securities totaled $861.6 million as of June 30, 2026.
GRAIL said Dr. Joshua Ofman will serve as its chief executive officer under an amended offer letter effective June 1, 2026. The letter sets his base salary at $800,000, a $2,000,000 restricted stock unit award, and severance terms that differ depending on whether a change in control occurs. The filing also furnished a May 31, 2026 investor presentation on NHS-Galleri and PATHFINDER 2 study data.
Base salary set at $800,000; variable compensation target is 100% of base salary from June 1, 2026, versus a prior 60% target that still applies to the part of 2026 before that date
RSU award with a $2,000,000 grant date value, vesting in equal annual installments on the first four anniversaries of May 31, 2026
Severance if terminated without cause or resigning for good reason: 24 months of base salary plus 200% of target bonus within the change-in-control period, or 12 months of base salary plus 100% of target bonus otherwise
Company will reimburse negotiation legal fees up to $25,000
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GRAIL, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →